The first platform trial for amyotrophic lateral sclerosis (ALS), which individually evaluated four experimental drugs, failed to meet key primary endpoints. Still, investigators view the trial as ...
When the results of the first-ever platform trial for amyotrophic lateral sclerosis (ALS) were published this February, the headlines might have seemed disappointing: four experimental drugs failed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback